CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money. CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money.

Dow Jones futures trade down 205pts following Monday’s vaccine rally

US markets rallied overnight on renewed covid-19 vaccine hopes, with the Dow Jones Industrial Average proving to be the best performing benchmark of the session.

Equity markets rally on vaccine hopes, futures market reverse the narrative

The Dow Jones Industrial Average and S&P 500 benchmarks rallied firmly overnight, while the tech-heavy Nasdaq 100 fell, after BioNTech and Pfizer announced that significant and promising progress had been made on the development of their covid-19 vaccine.

With a study comprised of over 40,000 participants, the companies reported that their experimental covid-19 vaccine ‘was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection.’

Importantly, both BioNTech and Pfizer noted that they were still collecting the required amount of safety and manufacturing data that the FDA required to grant a possible Emergency Use Authorization.

Despite such regulatory hurdles, it was reported that some 50 million doses of the vaccine could be produced by the end of CY20 and as many as 1.3 billion doses by the end of CY21.

Ultimately, while this vaccine news remains far from definitive – market participants responded as if it were a sure thing: The Dow Jones finished out the session up 834 points at the 29,157 point level, while the S&P 500 rose 1.17%. It was only the tech-centric Nasdaq 100 that fell behind, with the benchmark plunging 2.16% or 260 points to the 11,830 point level.

Looking at these market moves, IG Market Analyst Kyle Rodda said:

‘There was little concern for detail and nuance. But given the confidence of both companies that their vaccine was going to be a winner, maybe there need not be. Despite all the doubts, humanity and the marvels of medical science appears to moving ahead of schedule in ridding humanity of the virus.’

In that mad rush, perhaps investors were making a simple division – between the stocks that would benefit from a swift reopening of global commerce and those that wouldn’t, as much. Or maybe more technically – is it that valuations may finally be starting to matter again, with many high profile and high multiple tech stocks falling sharply on Monday.

Amazon and Facebook fell ~5%, Apple 2%, Netflix close to 9%, while Alphabet actually eked out a gain during yesterday’s session. Less prominent tech names that had run up during the height of the pandemic suffered even more pronounced losses: Used-car reseller Carvana plunged 7.55%, video software company Zoom crashed 17.55%, while e-commerce companies Etsy and MercadoLibre fell 17% and 10%, respectively.

Is tech’s outperformance over? Only time will tell.

Dow Jones lower following strong Monday session

Despite solid hopes of a vaccine, at the time of writing Dow Jones futures traded down around 205 points or 0.71% (10:02 PM New York time), suggesting the key US benchmark would open lower on Tuesday.

Nasdaq futures were also trading lower at the time of writing.

Want to trade US indices like the Nasdaq 100 and Dow Jones – long or short?

Create an IG trading account or log in to your existing account to get started now.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.